QIMOVA AS

Their core work

QIMOVA is a Danish medtech SME specializing in intelligent pressure injury prevention systems for wheelchair users, particularly those with spinal cord injuries. Their core technology integrates smart textile sensors embedded in seat cushions with real-time decision-making algorithms that detect dangerous pressure build-up and trigger automated repositioning via the wheelchair. They translate clinical knowledge about tissue viability and pressure ulcer formation into a hardware-software product that operates without requiring patient action. Their work sits at the intersection of ICT, assistive technology, and preventive healthcare.

What they specialise in

How they've shifted over time

QIMOVA's trajectory follows a classic SME Instrument path: they validated the concept with a Phase 1 feasibility grant (i-LiveRest, 2015–2016, €50k) and then secured a much larger Phase 2 development grant (LiveRest, 2018–2020, €1.4M) to bring the product to market readiness. The keyword set is entirely absent from the early project and fully populated in the later one, reflecting that the Phase 1 was essentially a business feasibility study while Phase 2 involved actual technical development — decision-making algorithms, tissue viability models, and full system integration. The focus has not shifted topic-wise; it has deepened from concept validation to engineered product.

QIMOVA appears to have been building toward a commercial product throughout their H2020 participation; if LiveRest reached its milestones, they are likely in a commercialization or post-market phase rather than seeking further R&D funding.

How they like to work

QIMOVA operated exclusively as a solo coordinator under the SME Instrument scheme, which is designed for individual companies rather than consortia — so the absence of partners reflects the funding model, not a deliberate avoidance of collaboration. This means there is no track record of consortium co-leadership or multi-partner coordination to assess. A future partner should expect to engage with them as a technology provider or product company rather than as an experienced consortium builder.

QIMOVA has no recorded consortium partners within H2020, as both projects were awarded under the SME Instrument, which funds single companies directly. Their collaborative network, if any, exists outside the H2020 formal partner structure — likely clinical partners, pilot sites, and distributors not captured in CORDIS data.

What sets them apart

QIMOVA occupies a specific niche that very few organizations address: the automated, sensor-driven prevention of pressure injuries in powered wheelchair users with spinal cord injuries — a population that cannot reposition themselves and is at extremely high clinical and cost risk. Their product-oriented approach, demonstrated by progressing from feasibility to a €1.4M development grant, distinguishes them from academic groups working on similar sensing problems. For any consortium addressing assistive technology, rehabilitation engineering, or digital health for people with disabilities, they bring a rare combination of proprietary textile sensor hardware and embedded control software in a validated clinical context.

Highlights from their portfolio

• LiveRest
  The largest grant in their portfolio at EUR 1.4M under SME Instrument Phase 2, representing a full product development effort combining smart textiles, real-time tissue viability assessment, and autonomous wheelchair control for spinal cord injury patients.
• i-LiveRest
  The Phase 1 feasibility predecessor that validated the business case for LiveRest, demonstrating a deliberate and disciplined two-stage commercialization strategy through EU funding instruments.